Cargando…

Registries supporting new drug applications

PURPOSE: Knowledge of the benefits and risks of new drugs is incomplete at the time of marketing approval. Registries offer the possibility for additional, post‐approval, data collection. For all new drugs, which were approved in the European Union between 2007 and 2010, we reviewed the frequency, t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jonker, Carla J., van den Berg, H. Marijke, Kwa, Marcel S.G., Hoes, Arno W., Mol, Peter G.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725674/ https://www.ncbi.nlm.nih.gov/pubmed/28983992 http://dx.doi.org/10.1002/pds.4332

Ejemplares similares

Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders
por: Jonker, Carla J., et al.
Publicado: (2021)

Inhibitor development in previously untreated patients with severe haemophilia: A comparison of included patients and outcomes between a clinical study and a registry‐based study
por: Jonker, Carla J., et al.
Publicado: (2020)

Risk factors in the development of stem cell therapy
por: Herberts, Carla A, et al.
Publicado: (2011)

Rare disease registries: potential applications towards impact on development of new drug treatments
por: Jansen-van der Weide, Marijke C., et al.
Publicado: (2018)

The Number of Concomitant Drugs and the Safety of Direct Oral Anticoagulants in Routine Care Patients with Atrial Fibrillation
por: van den Dries, Carline J., et al.
Publicado: (2020)

Registries for orphan drugs: generating evidence or marketing tools?
por: Hollak, Carla E. M., et al.
Publicado: (2020)

Drug Repurposing for Rare Diseases: A Role for Academia
por: van den Berg, Sibren, et al.
Publicado: (2021)

Medication Adherence Measurement Methods in Registration Trials Supporting the Approval of New Medicines: A Cross‐Sectional Analysis of Centralized Procedures in the European Union 2010–2020
por: Mantila, Katerina M., et al.
Publicado: (2022)

Drug development for exceptionally rare metabolic diseases: challenging but not impossible
por: Putzeist, Michelle, et al.
Publicado: (2013)

Patient Registries: An Underused Resource for Medicines Evaluation: Operational proposals for increasing the use of patient registries in regulatory assessments
por: McGettigan, Patricia, et al.
Publicado: (2019)

Translating Academic Drug Discovery Into Clinical Development: A Survey of the Awareness of Regulatory Support and Requirements Among Stakeholders in Europe
por: Kallio, Marko J., et al.
Publicado: (2022)

Smart Medication Adherence Monitoring in Clinical Drug Trials: A Prerequisite for Personalised Medicine?
por: Zijp, Tanja R., et al.
Publicado: (2019)

Future of the drug label: Perspectives from a multistakeholder dialogue
por: Gispen‐de Wied, Christine C., et al.
Publicado: (2019)

Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe
por: Jonker, Carla J., et al.
Publicado: (2022)

Effectiveness and costs of implementation strategies to reduce acid suppressive drug prescriptions: a systematic review
por: Smeets, Hugo M, et al.
Publicado: (2007)

β blockers for heart failure
por: Hoes, Arno W
Publicado: (2016)

A registry‐based algorithm to predict ejection fraction in patients with heart failure
por: Uijl, Alicia, et al.
Publicado: (2020)

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making
por: Bakker, Elisabeth, et al.
Publicado: (2022)

The changing incidence of Dengue Haemorrhagic Fever in Indonesia: a 45-year registry-based analysis
por: Karyanti, Mulya Rahma, et al.
Publicado: (2014)

Triage of frail elderly with reduced exercise tolerance in primary care (TREE). a clustered randomized diagnostic study
por: van Mourik, Yvonne, et al.
Publicado: (2012)

Modified Delphi procedure-based expert consensus on endpoints for an international disease registry for Metachromatic Leukodystrophy: The European Metachromatic Leukodystrophy initiative (MLDi)
por: Schoenmakers, Daphne H., et al.
Publicado: (2022)

Different impact of factor VIII products on inhibitor development?
por: van den Berg, H. Marijke
Publicado: (2016)

Collection of Data on Adverse Events Related to Medicinal Products: A Survey Among Registries in the ENCePP Resources Database
por: Plueschke, Kelly, et al.
Publicado: (2022)

Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study
por: de Vries, Sieta T., et al.
Publicado: (2019)

Advantages of the nested case-control design in diagnostic research
por: Biesheuvel, Cornelis J, et al.
Publicado: (2008)

Regulatory scientific advice in drug development: does company size make a difference?
por: Putzeist, Michelle, et al.
Publicado: (2010)

Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis
por: Lee, Kirby, et al.
Publicado: (2008)

A Mentee’s Baby Registry: Supporting New Academic Parents in 2020
por: Fertig, Elana J.
Publicado: (2020)

Genes, Culture and Conservatism-A Psychometric-Genetic Approach
por: Schwabe, Inga, et al.
Publicado: (2015)

Screening and follow-up care for cognitive and emotional problems after transient ischaemic attack and ischaemic stroke: a national, cross-sectional, online survey among neurologists in the Netherlands
por: Slenders, Jos, et al.
Publicado: (2021)

Borderline personality disorder in young people: associations with support and negative interactions in relationships with mothers and a best friend
por: Hessels, Christel J., et al.
Publicado: (2022)

A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

An expert-based mapping of healthcare system strategies to support rational drug prescribing in primary care across 13 European countries
por: Rotar, Alexandru M., et al.
Publicado: (2020)

Short-Term Outcomes of Elective High-Risk PCI with Extracorporeal Membrane Oxygenation Support: A Single-Centre Registry
por: Griffioen, Alexander M., et al.
Publicado: (2022)

Strategy to recognize and initiate treatment of chronic heart failure in primary care (STRETCH): a cluster randomized trial
por: van Riet, Evelien ES, et al.
Publicado: (2014)

Safety of off‐label dose reduction of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: van den Dries, Carline J., et al.
Publicado: (2022)

Number of Patients Studied Prior to Approval of New Medicines: A Database Analysis
por: Duijnhoven, Ruben G., et al.
Publicado: (2013)

Extended prediction rule to optimise early detection of heart failure in older persons with non-acute shortness of breath: a cross-sectional study
por: van Riet, Evelien E S, et al.
Publicado: (2016)

E-Pal
por: van den Berg, Frank, et al.
Publicado: (2021)

How can patient registries facilitate guideline-based healthcare? A retrospective analysis of the CEDATA-GPGE registry for pediatric inflammatory bowel disease
por: Leiz, M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3d8fl1jg053b0kfm8r5r1kvib2